Comparative effectiveness of combination therapy with <scp>SGLT</scp> ‐2 inhibitors and <scp>GLP</scp> ‐1 <scp>RAs</scp> compared with <scp>SGLT</scp> ‐2 inhibitors in individuals with type 2 diabetes: A prevalent new‐user cohort study

In this large real-world cohort, combination therapy with SGLT-2 inhibitors and GLP-1 RAs was associated with a lower hazard of all-cause mortality, while most secondary cardiorenal outcomes showed generally favourable but imprecise estimates. These findings suggest that sustained concurrent use of both drug classes may offer meaningful clinical benefits in routine practice, although residual confounding cannot be fully excluded.